Deprecated!
This application is deprecated. Please use the latest version of the tool here.
Please cite:
I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni, G. Georgakilas, T. Vergoulis, I. Kanellos, I-L. Anastasopoulos, S. Maniou, K. Karathanou, D. Kalfakakou, A. Fevgas, T. Dalamagas and A. G. Hatzigeorgiou. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucl. Acids Res. (2014)
Data Download:
DIANA-TarBase v7 is available for scientific non-profit and non-commercial use! Download TarBase v7 by following this link
|
||||||||
Related Pathways
Publication year
Prediction score
Filters
Selected:
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Remove all
Species
Method Type
Method
Regulation type
Validation type
Validated as
Source
Publication year
Prediction score
Loading... |
Wait until the result set is completed... |
Gene name
miRNA name
Methods
Pred.Score
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136851-145136871 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134021-145134049 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145136851-145136871 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136851-145136871 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136851-145136872 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134021-145134045 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145136851-145136872 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136851-145136872 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135361-145135379 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136869-145136884 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136552-145136575 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136552-145136575 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136552-145136561 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136552-145136561 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136552-145136561 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134253-145134269 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135316-145135330 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133869-145133886 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133671-145133681 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145133691-145133717 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133694-145133716 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133694-145133716 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133694-145133716 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133694-145133716 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133835-145133853 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135316-145135331 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136567-145136595 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136567-145136595 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136567-145136595 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136567-145136595 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135703-145135728 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135703-145135726 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135703-145135729 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136552-145136560 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136552-145136560 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136391-145136413 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133671-145133681 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145133691-145133717 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135579-145135607 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145142249-145142268 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136137-145136158 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133699-145133723 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137050-145137069 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133699-145133725 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137050-145137068 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162676 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162676 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162667-145162686 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162673 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162673 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162673 (UNKNOWN)
Breast carcinoma cell line, triple negative. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162675 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162675 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135816-145135837 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145138510-145138535 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145162649-145162675 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134312-145134340 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162676 (UNKNOWN)
Primary human umbilical vein endothelium. AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162676 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162676 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162676 (UNKNOWN)
Breast carcinoma cell line, triple negative. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135400-145135419 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135787-145135809 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137047-145137068 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134295 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134295 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137047-145137068 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134295 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134295 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137047-145137074 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134298 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134298 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134298 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134298 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137047-145137074 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134297 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134297 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134297 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134468-145134490 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137047-145137055 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134302 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134302 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137047-145137055 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134302 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134302 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137047-145137055 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134283 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134283 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137047-145137055 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134283 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134276-145134283 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134272-145134297 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135843-145135866 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135843-145135866 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134272-145134293 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135848-145135875 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135784-145135801 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135784-145135801 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162678-145162701 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136391-145136413 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145150871-145150888 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134261-145134287 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137098-145137126 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162678-145162686 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162678-145162686 (UNKNOWN)
Primary human umbilical vein endothelium. AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135779-145135803 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136226-145136244 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136553-145136579 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136553-145136579 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136226-145136245 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136553-145136578 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136867-145136890 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136226-145136247 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145138493-145138512 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136226-145136247 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136206-145136230 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134053-145134077 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134330-145134352 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145141405-145141420 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145141405-145141420 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134738-145134759 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145137330-145137343 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135824-145135849 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135870-145135892 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136207-145136234 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135582-145135600 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135582-145135600 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135251-145135267 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162649-145162668 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134319-145134347 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133975-145133998 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133655-145133675 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133655-145133675 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 3 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133661-145133680 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162653-145162679 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162653-145162679 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162653-145162679 (UNKNOWN)
Breast carcinoma cell line, triple negative. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136226-145136247 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135406-145135414 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145162654-145162682 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145143386-145143404 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133883-145133899 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145137792-145137818 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145141414-145141437 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145141414-145141437 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 3 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145141414-145141437 (UNKNOWN)
Breast carcinoma cell line, triple negative. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-651
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136917-145136939 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
ebv-miR-BART20-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135311-145135334 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-331-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136008-145136030 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-3677-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135850-145135878 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-4661-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135862-145135885 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-17-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135301-145135323 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-24-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145141427-145141454 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-181a-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133733-145133757 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-181c-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133733-145133754 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-218-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134611-145134620 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-138-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145142243-145142267 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-331-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145138025-145138048 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-335-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133650-145133676 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
ebv-miR-BART2-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133725-145133746 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr4:145137029-145137044 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145133725-145133746 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-18b-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145141414-145141434 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145141414-145141434 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 3 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-432-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145138523-145138550 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-584-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162670-145162681 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162670-145162681 (UNKNOWN)
Breast carcinoma cell line, triple negative. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-16-2-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162682-145162695 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 3 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145162682-145162695 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-221-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135872-145135892 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-1226-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135860-145135881 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
ebv-miR-BART15
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136551-145136568 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-483-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145135774-145135788 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
ebv-miR-BART18-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:145136852-145136859 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-182-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
Biotin pull-downs, microarrays
Biotin-Microarrays
POSITIVE
INDIRECT
Tarbase 7.0
OTUD4 (hsa)
hsa-miR-522-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
We applied an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRN cluster, highly expressed in poorly differentiated cancers. To identify miRN targets, we sequenced full-length transcripts captured by a biotinylated miRN mimic. Within these targets, mostly noncanonical MREs were identified by sequencing RNase-resistant fragments.
AGO-IP
POSITIVE
INDIRECT
Tarbase 7.0
chr4:146055887-146055927 (3UTR)
We applied an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRN cluster, highly expressed in poorly differentiated cancers. To identify miRN targets, we sequenced full-length transcripts captured by a biotinylated miRN mimic. Within these targets, mostly noncanonical MREs were identified by sequencing RNase-resistant fragments.
IMPACT-Seq
POSITIVE
DIRECT
Tarbase 7.0
chr4:146058442-146058464 (3UTR)
We applied an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRN cluster, highly expressed in poorly differentiated cancers. To identify miRN targets, we sequenced full-length transcripts captured by a biotinylated miRN mimic. Within these targets, mostly noncanonical MREs were identified by sequencing RNase-resistant fragments.
IMPACT-Seq
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:145134753-145134775 (3UTR)
We applied an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRN cluster, highly expressed in poorly differentiated cancers. To identify miRN targets, we sequenced full-length transcripts captured by a biotinylated miRN mimic. Within these targets, mostly noncanonical MREs were identified by sequencing RNase-resistant fragments.
Luciferase Reporter Assay
POSITIVE
DIRECT
Tarbase 7.0